[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644801":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":10,"responsibleParty":24,"collaborators":26,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":32,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Vaccinated group",null,"Individuals with documented receipt of an RSV vaccine in EHR data. Vaccines included: ABRYSVO® (Pfizer),AREXVY® (GSK), mRESVIA® (Moderna)",{"label":13,"type":10,"description":14,"interventionNames":10},"Unvaccinated comparator group:","Individuals not yet vaccinated at cohort entry, but otherwise eligible",[16],{"name":17,"affiliation":5,"role":18},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[20],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",{"type":25,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[27],{"name":28,"class":29},"Ividence","UNKNOWN","100644801","real-world-effectiveness-of-rsv-vaccines-among-adults-using-target-trial-emulation-in-epic-cosmos-100644801",false,"NCT07673081","Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos","Inclusion: Vaccinated Cohort\n\nPatients must meet all the following inclusion criteria to be eligible for inclusion in the vaccinated cohort:\n\nAdults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.\n\nHave a documented administration of ABRYSVO® (or AREXVY®，mRESVIA® in the later phase) in Epic Cosmos on or after August 2023.\n\nThe index date for vaccinated individuals will be defined as the date of RSV vaccination.\n\nUnvaccinated Cohort\n\nPatients must meet all the following inclusion criteria to be eligible for inclusion in the unvaccinated cohort:\n\nAdults meet the age criteria at the index date. Non-pregnant at the index date. Have at least one clinical encounter recorded in Epic Cosmos database during the 12 months prior to the index date.\n\nHave no documented receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date.\n\nThe index date for unvaccinated individuals will be defined as the start date of each sequential trial (e.g., 1st date of each month) in which they met eligibility criteria.\n\nExclusion:\n\nVaccinated Cohort\n\nPatients meeting any of the following criteria will not be included in the vaccinated cohort:\n\nIndividual with receipt of any RSV vaccine in Epic Cosmos prior to the trial start date, as defined above (applicable to all analyses except for the analysis of recipients of multiple doses).\n\nNon-US residents. Unvaccinated Cohort\n\nPatients meeting any of the following criteria will not be included in the unvaccinated cohort:\n\nIndividual with receipt of any RSV vaccine in Epic Cosmos on or prior to the trial start date, as defined above.\n\nNon-US residents. Patients must meet all the inclusion criteria and none of the exclusion criteria to meet eligibility requirements.","ALL","18 Years",{"count":39,"type":40},293334,"ESTIMATED","OBSERVATIONAL","Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework",[44],"Respiratory Syncytial Virus (RSV)",[46,47],"RSV, Respiratory Syncytial Virus","Vaccine effectivness","NOT_YET_RECRUITING","2026-06-22",{"date":51,"type":52},"2026-06-29","ACTUAL",{"date":54,"type":40},"2026-06-20",{"date":56,"type":40},"2026-11-30",{"name":5,"class":6}]